DSS TheraDoc Supported COVID-19 Monoclonal Antibody Infusions Workflow at a Veterans Affairs Medical Center
With the potential rise of super bugs at VA facilities, the Department of Veterans Affairs (VA) has been taking proactive steps to enhance its overall clinical surveillance for antimicrobial stewardship and infectious disease control.
At ID Week 2022, VA executives presented a poster session titled, “Implementation of a Workflow for COVID-19 Monoclonal Antibody Infusions at a Veterans Affairs Medical Center.”
The session highlighted how high-risk patients with mild to moderate disease were identified as a group who would benefit from COVID-19 monoclonal antibody (mAB) treatment to mitigate progression to severe disease or hospitalization.
At a VA medical center in Washington, D.C., the DSS TheraDoc solution was used to rapidly identify outpatients for screening. As a result, 198 outpatients were screened and 16 received COVID-19 mAB infusions between January 2, 2021 to May 31, 2021.
The paper concludes that an agile workflow “helped facilitate the changes necessary to provide our patients the opportunity to receive potentially life-saving therapies.”
TheraDoc, DSS’s industry leading software decision support tool that provides real-time electronic clinical surveillance for antimicrobial stewardship and infectious disease, has been gaining traction at 59 VAMCs around the United States.
DSS also recently launched a new TheraDoc Medical Device Interface. The TheraDoc Medical Device Interface tracks and monitors device insertions and removals, associates device presence with healthcare-associated infections (HAIs) and calculates device days for evaluation and required reporting.
This poster session is a prime example of how the DSS TheraDoc solution can effectively enhance antimicrobial stewardship and infectious disease treatment for any VA facility.
Please click here to learn more about DSS TheraDoc solution. In addition, to learn about DSS’ suite of federal health IT solutions, please click here.